Observational studyScience progress
A retrospective observational analysis of the global burden of smoking-attributable prostate, bladder, and kidney cancers among adults aged 40 years and older: Based on the global burden of disease study 2021 with projections to 2045.
Observational study in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveSmoking remains a significant risk factor for prostate, bladder, and kidney cancers. The disease burden and smoking-attributable carcinogenic effects are particularly concentrated in adults aged 40 years and older, making this age group critical for targeted prevention. We aimed to analyze the global, regional, and national disease burden of smoking-attributable prostate, bladder, and kidney cancers exclusively among adults aged 40 years and older from 1990 to 2021, and to provide long-term projections to 2045 for evidence-based tobacco control and cancer prevention strategies.MethodsThis retrospective observational study used data from the Global Burden of Disease Study 2021, we assessed age-standardized mortality rate (ASMR) and disability-adjusted life year rate (ASDR), along with absolute deaths and disability-adjusted life years (DALYs). Trends were evaluated using estimated annual percentage change (EAPC), and future burden was projected using the Nordpred model.ResultsFrom 1990 to 2021, absolute DALYs and deaths increased globally, while ASDR and ASMR declined. In 2021, DALYs for prostate and kidney cancers peaked at ages 65-69, and for bladder cancer at 70-74. High-SDI regions had the highest ASDR for prostate and kidney cancers, while middle-high-SDI regions led in bladder cancer. ASDR and ASMR decreased for prostate and bladder cancers across most SDI regions, but kidney cancer rates rose in Middle and Low-middle-SDI regions. By 2045, prostate cancer ASDR/ASMR are projected to increase after 2035, while bladder and kidney cancers will continue declining, though absolute burden will rise.ConclusionSmoking-attributable urological cancers remain a major public health challenge. Despite declining age-standardized rates, absolute burden is growing, particularly among older adults and in middle/low-SDI regions. Strengthened tobacco control, early screening, and optimized resource allocation are critical to reducing future burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.